The New Drug Application for Patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of hereditary ATTR (hATTR) amyloidosis is under priority review by the FDA, with a decision expected on August 11, 2018. Patisiran is developed by Alnylam Pharmaceuticals (ALNY), using Arbutus Biopharma’s Lipid Nanoparticle (LNP) delivery technology. Successful approval of Patisiran will trigger a royalty entitlement to Arbutus from Alnylam.Credit Suisse analyst Alethia Young expects Patisiran sales to peak by 2023 at $1.5 billion.Tegsedi, a drug developed by Akcea and Ionis Pharmaceuticals, for the similar indication, hereditary transthyretin amyloidosis, is under FDA review with a decision expected on October 6, 2018. Tegsedi was approved in the European Union as recently as July 11, 2018.ALNY closed Wednesday’s (Jul 25) trading at $105.74, up 3.00%.